Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Cancer disease is one of the leading cause of death worldwide. The growing burden of different cancer patient has provided an opportunity to market key player to launch and introduced new oncology/cancer drugs. The different type of cancer are observed in patient like kidney cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophagus cancer, liver cancer, lung cancer, prostate cancer, stomach cancer. These are driving the market growth to do research and development of the oncological drug development. The growing demand from the end user is further boosting the market demand is expected to witness growth at the highest pace during the forecast period.
The market is driven by rising in incidence of
various cancer conditions further providing opportunity to the market key
player to launch innovative and advanced drugs in oncology/cancer drugs
market. In addition increase in
popularity of advance therapies is further boosting the market demand.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the oncology/cancer drugs market. In addition, complete analysis of changes on the oncology/cancer drugs market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market.
The oncology/cancer drugs market is segmented based on by drug class type, indication, route of drug administration, end user and geography.
The oncology/cancer drugs are available in different types including chemotherapy, targeted therapy, immunotherapy, hormonal therapy
The targeted therapy is anticipated to
dominate in the global oncology/cancer drugs market. The growth is due to
potential of targeted therapy to identify the certain type of cancer cells and
target cancerous cells. The growing
innovation in the therapy is contributing in the growth of the oncology/cancer
drugs market. Whereas Immunotherapy is expected to witness the growth at
highest pace during the forecast period. The immunotherapy majorly uses the oncology/cancer
drugs by providing immunity to system for attacking the cancer cells.
The oncology/cancer drugs are present for
different indication including kidney cancer, bladder cancer, breast cancer,
cervical cancer, colorectal cancer, esophagus cancer, liver cancer, lung
cancer, prostate cancer, stomach cancer. Breast cancer is expected to witness
the growth at the rate during the forecast period. The market has the demand
owing increasing patient of breast cancer. In addition these drug directly
target and destroy the breast cancer cells. The composition of drugs is key
factor driving the growth of the market.
The oncology/cancer drugs are available through route of drug administration like intravenous, oral, subcutaneous, intra-muscular, intraperitoneal, intraventricular/intrathecal. Oral route of drug administration is widely used for treatment of cancer patient using oncology/cancer drugs. However intravenous is expected to witness the growth at significant rate during the forecast period.
ONCOLOGY/CANCER DRUGS MARKET BY END USER
The oncology/cancer drugs have major end user in specialty centers, hospitals & clinics. Hospital & clinics are anticipated to lead in the market owing to growing number of cancer patient in hospital for the diagnosis and treatment.
Geographically the global oncology/cancer drugs market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW). North America is expected to dominate in the global oncology/cancer drugs market owing to increasing adoption of advanced oncology/cancer drugs in the region. In addition the developed healthcare facilities, treatment for cancer patient is further fueling the demand of the global oncology/cancer drugs market. Also, presence of key players in the region is driving the market growth. Whereas Asia Pacific is expected to grow at the fastest pace during the forecast period attributing to increasing research and development activities on cancer drugs. In addition, rising cases and awareness for oncology/cancer drugs is propelling market growth in Asia Pacific region.
ONCOLOGY/CANCER DRUGS MARKET KEY PLAYER
The key players in oncology/cancer drugs market are Novartis AG, Almatic Pharma, Pfizer, AstraZeneca Pharmaceuticals, Astellas Pharma, Puma Biotechnology, Clovis Oncology, Takeda Pharmaceutical Company Limited, Amgen Inc., Sanofi, Bayer HealthCare Pharmaceutical, Jazz Pharmaceutical, EMD Serono, Celgene Corporation, GlaxoSmithLine PLC, Eli Lily, and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd. and Janssen Global Services, LLC, among others.
The report analyses the global in oncology/cancer drugs market based on by drug class type, indication, route of drug administration, end user and geography. The oncology/cancer drugs are available in different types including chemotherapy, targeted therapy, immunotherapy, hormonal therapy. The oncology/cancer drugs are present for different indication including kidney cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophagus cancer, liver cancer, lung cancer, prostate cancer, stomach cancer. The oncology/cancer drugs are available through route of drug administration like intravenous, oral, subcutaneous, intra-muscular, intraperitoneal , intraventricular/intrathecal. The oncology/cancer drugs have major end user in specialty centers, hospitals & clinics. Geographically the global oncology/cancer drugs market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW)
The key players in oncology/cancer drugs market are Novartis AG, Almatic Pharma, Pfizer, AstraZeneca Pharmaceuticals, Astellas Pharma, Puma Biotechnology, Clovis Oncology, Takeda Pharmaceutical Company Limited, Amgen Inc., Sanofi, Bayer HealthCare Pharmaceutical, Jazz Pharmaceutical, EMD Serono, Celgene Corporation, GlaxoSmithLine PLC, Eli Lily, and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd. and Janssen Global Services, LLC, among others.
Why to buy this report:
